Leaflet: information for the user
Manidipino Combix 20 mg tablets EFG
Manidipine dihydrochloride
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
Manidipino Combix contains manidipine dihydrochloride as the active ingredient. Manidipine dihydrochloride belongs to a group of medicines called calcium channel blockers that block the flow of calcium in the smooth muscle cells of blood vessels, causing vasodilation and the corresponding reduction in blood pressure.
Manidipino Combix is indicated for the treatment of mild to moderate essential hypertension (high blood pressure).
Do not take Manidipino Combix
Manidipino Combix should not be administered to children or adolescents under 18 years of age.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Manidipino Combix:
You should also inform your doctor:
Taking Manidipino Combix with other medications
Inform your doctor or pharmacist that you are taking, have taken recently, or may have to take any other medication.
It is especially important to inform your doctor if you are taking any of the following medications:
If you are taking any of the medications mentioned above, your doctor may prescribe another medication or adjust the dose of Manidipino Combix or another medication.
Taking Manidipino Combix with food, drinks, and alcohol
Do not take Manidipino Combix with grapefruit juice, as blood pressure may drop too low. Consuming alcohol may enhance the blood pressure-lowering effect of Manidipino Combix.
Pregnancy, lactation, and fertility
If you are pregnant or breastfeeding, or think you may be pregnant, or are trying to become pregnant, consult your doctor before using this medication.
Pregnancy
Since Manidipino Combix should not be taken during pregnancy, your doctor will recommend that you stop treatment before becoming pregnant or as soon as you know you are pregnant, and will advise on the appropriate treatment.
Lactation
Consult your doctor if you are breastfeeding or before starting breastfeeding. Manidipino Combix should be avoided in women who are breastfeeding, if the Manidipino Combix treatment cannot be discontinued, your doctor will advise you to stop breastfeeding.
Consult your doctor or pharmacist before using any medication.
Driving and operating machinery
Occasionally, in some patients during treatment for high blood pressure, this medication may cause dizziness. In these cases, you should inform your doctor before engaging in activities such as driving or operating machinery.
Manidipino Combix contains lactose
This medication contains lactose. If your doctor has indicated that you have a certain sugar intolerance, consult with them before taking this medication.
Follow exactly the administration instructions for this medication as indicated by your doctor. If in doubt, consult your doctor again.
At the start, the usual dose of Manidipino Combix is 10 mg per day. After 2-4 weeks, if the reduction in blood pressure is considered insufficient, your doctor may increase this dose to 20 mg once a day (usual maintenance dose).
If you are elderly, or if you suffer from any kidney or liver disease, your doctor may prescribe a reduced dose.
Use in Children and Adolescents
Children and adolescents should not take Manidipino Combix (see section “Do not take Manidipino Combix”).
Administration
Manidipino Combix should be taken in the morning after breakfast. The tablet should be swallowed, without chewing, with an adequate amount of water. Try to take your daily dose at the same time each day.
Treatment Duration
It is essential that you continue taking Manidipino Combix until your doctor tells you otherwise. Take exactly the prescribed dose and do not modify it without speaking with your doctor first.
If You Take More Manidipino Combix Than You Should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If You Forget to Take Manidipino Combix
If you forget to take a dose of Manidipino Combix, take the next dose as prescribed. Do not take a double dose to compensate for the missed doses.
It is essential that you continue taking Manidipino Combix until your doctor tells you otherwise.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, Manidipino Combix can cause side effects, although not everyone will experience them.
If side effects occur, they will mainly be mild and temporary. However, some side effects can be serious and require medical attention.
Frequent side effects(may affect between 1 and 10 in 100 patients):
Fluid accumulation in tissues causing inflammation (edema), hot flushes, dizziness, nausea, headache, palpitations.
Less frequent side effects(may affect between 1 and 10 in 1,000 patients):
Prickling or painful numbness (paresthesia), increased heart rate (tachycardia), reduced blood pressure (hypotension), difficulty breathing (dyspnea), weakness, dry mouth, nausea, vomiting, constipation, gastrointestinal discomfort, skin rash, skin inflammation with redness and itching (eczema), transient alterations in laboratory tests of some enzymes (ALT, AST, LDH, GammaGT, ALP, blood urea nitrogen and creatinine in blood).
Rare side effects(may affect between 1 and 10 in 10,000 patients):
Irritability, skin redness, itching, stomach pain (gastralgia), abdominal pain, drowsiness, chest pain, chest pain due to inadequate blood supply to the heart (angina pectoris), diarrhea, decreased appetite (anorexia), abnormal results in blood tests (e.g., increased bilirubin in blood), jaundice.
Very rare side effects(may affect fewer than 1 in 10,000 patients):
Myocardial infarction, in patients with pre-existing angina pectoris may experience an increase in frequency, duration or severity of these attacks, inflammation or alteration of the gums, which require careful dental attention but usually resolve with suspension of treatment.
Side effects of unknown frequency(frequency cannot be estimated with available data):
Muscle pain.
Swelling of the breast with or without pain in men (gynecomastia)
Abnormal skin redness (erythema multiforme), skin disease with abnormal redness and scales (dermatitis exfoliativa)
Cloudy liquid (when undergoing dialysis through a tube in the abdomen).
If you experience side effects, consult your doctor or pharmacist, even if they are side effects that do not appear in this prospectus.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is possible side effects that do not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
No special storage conditions are required.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Manidipino Combix 20 mg tablets
Appearance of the product and contents of the packaging
Oval, biconvex tablets, yellow in color, scored on one face and smooth on the other.
OPA/AL/PVC/Al blisters.
Packaging of 28 tablets.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Combix Laboratories, S.L.U.
C/ Badajoz 2, Building 2
28223 Pozuelo de Alarcón (Madrid)
Spain
Responsible for manufacturing
Zydus France
ZAC les Hautes Patures
Parc d’activités des Peupliers
25 Rue des Peupliers
92000 Nanterre
France
or
Centre Spécialités Pharmaceutiques
ZAC des Suzots
35 rue de la Chapelle
63450 Saint Amant Tallende
France
Last review date of this leaflet: September 2024
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) at http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.